Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1999 1
2007 1
2008 1
2009 1
2012 1
2013 1
2014 2
2015 1
2016 4
2017 2
2018 1
2019 1
2020 2
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.
Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, Marcus D, Anderton J, Watkins A, Coates Ulrichsen J, Brohawn P, Higgs BW, McCourt M, Jones H, Harper JA, Morrow M, Valge-Archer V, Stewart R, Dovedi SJ, Wilkinson RW. Mosely SI, et al. Among authors: leyland r. Cancer Immunol Res. 2017 Jan;5(1):29-41. doi: 10.1158/2326-6066.CIR-16-0114. Epub 2016 Dec 6. Cancer Immunol Res. 2017. PMID: 27923825 Free article.
Epigenomic Modifications Mediating Antibody Maturation.
Sheppard EC, Morrish RB, Dillon MJ, Leyland R, Chahwan R. Sheppard EC, et al. Among authors: leyland r. Front Immunol. 2018 Feb 26;9:355. doi: 10.3389/fimmu.2018.00355. eCollection 2018. Front Immunol. 2018. PMID: 29535729 Free PMC article. Review.
Structured reflection on shared decision making.
Leyland R, Heath M, Neve H, Maynard V. Leyland R, et al. Clin Teach. 2021 Feb;18(1):55-61. doi: 10.1111/tct.13233. Epub 2020 Aug 20. Clin Teach. 2021. PMID: 32815256
miR-155: an ancient regulator of the immune system.
Vigorito E, Kohlhaas S, Lu D, Leyland R. Vigorito E, et al. Among authors: leyland r. Immunol Rev. 2013 May;253(1):146-57. doi: 10.1111/imr.12057. Immunol Rev. 2013. PMID: 23550644 Review.
Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity.
Harper J, Burke S, Travers J, Rath N, Leinster A, Navarro C, Franks R, Leyland R, Mulgrew K, McGlinchey K, Brown L, Dovedi SJ, Koopmann JO, Durham NM, Cheng X, Jin H, Eyles J, Wilkinson RW, Carroll D. Harper J, et al. Among authors: leyland r. Mol Cancer Ther. 2021 Sep;20(9):1723-1734. doi: 10.1158/1535-7163.MCT-20-0902. Epub 2021 Jun 17. Mol Cancer Ther. 2021. PMID: 34224361 Free PMC article.
The miR-155-PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation.
Lu D, Nakagawa R, Lazzaro S, Staudacher P, Abreu-Goodger C, Henley T, Boiani S, Leyland R, Galloway A, Andrews S, Butcher G, Nutt SL, Turner M, Vigorito E. Lu D, et al. Among authors: leyland r. J Exp Med. 2014 Oct 20;211(11):2183-98. doi: 10.1084/jem.20140338. Epub 2014 Oct 6. J Exp Med. 2014. PMID: 25288398 Free PMC article.
19 results